vimarsana.com

Page 10 - அடித்தளம் சண்டை குருட்டுத்தன்மை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nate Light, Revered Exec Who Built Sterling, Dies

Share Nathan “Nate” Light (pictured), the affable yet driven executive who helped turn Sterling Jewelers into a retail powerhouse, died on March 12 in Palm Beach, Fla. He was 86. After serving in the U.S. Navy, Light started his industry career as a salesman at Rose Jewelers in Detroit, working for 65 cents an hour. He later became the company’s vice president of merchandising. After that, he worked as a buyer, general manager, and executive vice president at another Detroit jeweler, Shifrin-Willens. In 1977, Light became chairman and CEO of Sterling Jewelers, in a move that proved fateful not only for his career but for the entire U.S. jewelry industry. When Light first joined the Akron, Ohio–based company, it was still a small, family-owned, 32-store chain. Under his leadership, Sterling grew to encompass 117 stores. In 1987, it was acquired by Ratners Group (now Signet), a British jeweler seeking a U.S. presence.

Foundation Fighting Blindness To Jointly Host Online Continuing Medical Education (CME, COPE) Webinar

Press release content from PR Newswire. The AP news staff was not involved in its creation. Foundation Fighting Blindness To Jointly Host Online Continuing Medical Education (CME, COPE) Webinar March 2, 2021 GMT (PRNewsfoto/Foundation Fighting Blindness) COLUMBIA, Md., March 2, 2021 /PRNewswire/ The Foundation Fighting Blindness, the world’s leading private funding source for retinal degenerative disease research, will host an online continuing medical education (CME and COPE) course on Monday, April 5, 2021, at 7:00 p.m. Eastern Time. More than 40 clinical trials for emerging retinal degenerative disease therapies are underway. The studies provide hope for patients and the opportunity for them to participate in the research.

ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results

ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results Phase 2/3 pivotal Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021 QR-421a Stellar Phase 1/2 trial for Usher syndrome and non-syndromic retinitis pigmentosa interim analysis on track for late Q1/early Q2 2021 Further pipeline progress anticipated with first clinical data in 2021 from QR-1123 program for autosomal dominant retinitis pigmentosa and QR-504a clinical study in Fuchs endothelial corneal dystrophy expected to start in H1 2021 Cash runway into 2023

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.